Drugs / MQ719
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05859074 | May 2023 → May 2028 expected | Kaposi's sarcoma, cutaneous neuroendocrine carcinoma, extramammary Paget disease, head and neck squamous cell carcinoma +6 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MQ719 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05859074 ↗ |
| Route | Other | “injected directly into the patient's tumor (intratumorally)” NCT05859074 ↗ |